Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
The authors of a systematic review and meta-analysis recommended reconsideration of guidelines on sodium-glucose cotransporter-2 (SGLT-2) inhibitors to increase use among patients at risk of cardiovascular disease.
Patients with diabetes and mild-to-moderate cardiomyopathy had higher mortality risk than nondiabetic patients with severe cardiomyopathy, suggesting that they may benefit from implantable cardioverter defibrillators, according to the study authors.
While weight loss and improved fitness should both be recommended for patients with diabetes, these observational results highlight the need for further research to test whether prevention strategies focusing on improving
About one-third of men approached in barbershops owned by black individuals were willing to be screened for diabetes, and 9% of them had undiagnosed diabetes while 28% had prediabetes.
The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).
Incorporating intensive weight management with a low-carb diet into standard group medical visits for patients with diabetes “should be considered as an alternative, noninferior approach for glycemic management that has additional clinical
They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings “highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
A retrospective cohort study used electronic health record data from one health care system to assess postoperative mortality and readmission rates in adults who had major surgery.
In a propensity-matched Scandinavian study, new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had a lower risk of renal replacement therapy and hospital admission for renal events than new users of dipeptidyl peptidase-4 (DPP-4)